Date: 2012-02-09
Type of information: Co-promotion agreement
Compound: Xarelto® (rivaroxaban)
Company: Bayer (Germany) - Almirall (Spain)
Therapeutic area: Cardiovascular diseases - Cerebrovascular diseases
Type agreement: co-promotion
Action mechanism: anticoagulant agent/oral direct Factor Xa inhibitor
Disease: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors, treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults, and prevention of VTE in adult patients undergoing elective hip or knee replacement surgery.
Details: Bayer and Almirall have announced an agreement to co-promote Rivaroxaban (Xarelto®) in Spain beginning in the coming months. Rivaroxaban, an oral anticoagulant developed by Bayer, is the only new oral anticoagulant approved in three indications across Europe (prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors, treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults, and prevention of VTE in adult patients undergoing elective hip or knee replacement surgery.)
Financial terms:
Latest news:
